Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Carcinoma, Epidermoid

imatinib mesylate has been researched along with Carcinoma, Epidermoid in 37 studies

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (37.84)29.6817
2010's22 (59.46)24.3611
2020's1 (2.70)2.80

Authors

AuthorsStudies
Anwar, MF; Siraj, B; Tanveer, F; Zarina, S1
Cordes, N; Dickreuter, E; Koppenhagen, P1
Colegio, OR; Liu, LS1
Cottrell, CE; Govindan, R; Hagemann, IS; Javidan-Nejad, C; Pfeifer, JD1
Aderhold, C; Faber, A; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, JD; Stern-Straeter, J; Umbreit, C1
Fujii, M; Honma, M; Iizuka, H; Ishida-Yamamoto, A; Iwasaki, T; Kishiyama, K; Takahashi, H; Takahashi, I1
Ebi, H; Faber, AC; Huynh, TG; Kita, K; Kitai, H; Kotani, H; Mino-Kenudson, M; Nanjo, S; Ooi, A; Yano, S1
Alfieri, S; Bergamini, C; Bossi, P; Granata, R; Imbimbo, M; Licitra, L; Locati, L; Pala, L1
Inayat, F; Saif, MW1
Aguilera, J; Chen, JS; Chu, TS; Lopez, JP; Ongkeko, WM; Pardo, FS1
Bran, B; Bran, G; Hörmann, K; Riedel, F1
Arias-Bonfill, D; Candelaria, M; Cantú, D; Chanona, J; Chávez-Blanco, A; Dueñas-González, A; Pérez, C1
Bzyl, J; Fusenig, NE; Heusel, J; Kiessling, F; Lederle, W; Linde, N; Mueller, MM; Skobe, M; Woenne, EC; Zwick, S1
Hong, MH; Huang, PY; Luo, DH; Mai, HQ; Zhang, L; Zhang, X1
Allen, A; Hsueh, CT; Huang, CH; Kelly, K; Mayo, M; Smith, H; Tawfik, O; Uypeckcuat, AM; Van Veldhuizen, PJ; Wick, J; Williamson, SK1
Anders, C; Erben, P; Faber, A; Hofheinz, RD; Hörmann, K; Riedel, F; Rotunno, S; Sauter, A; Schultz, JD; Sommer, JU; Thorn, C1
Anders, C; Erben, P; Hofheinz, RD; Hörmann, K; Rotunno, S; Sauter, A; Schultz, JD; Sommer, JU; Stern-Straeter, J1
O'Bryan, KW; Ratner, D1
Erben, P; Faber, A; Hofheinz, RD; Hörmann, K; Mühlheim, K; Sauter, A; Schultz, JD; Sommer, JU; Thorn, C1
Blumenschein, GR; Charnsangavej, C; Fossella, FV; Fujimoto, J; Hong, WK; Kies, MS; Lee, JJ; Liu, S; Marom, EM; Papadimitrakopoulou, V; Stewart, DJ; Tran, HT; Tsao, AS; Wistuba, II1
Erben, P; Faber, A; Hoedt, S; Hofheinz, RD; Hörmann, K; Sauter, A; Schultz, JD; Sommer, JU; Thorn, C1
Chinen, I; Enomoto, T; Hoffman, RM; Kimura, T; Mekada, E; Mizushima, H; Moribe, H; Murata, T; Ueda, Y; Yagi, S; Yoshino, K1
Agarwal, JP; Banavali, S; Budrukkar, A; Chatturvedi, P; D'Cruz, A; Laskar, SG; Murthy, V; Muttagi, S; Shahid, T1
Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R1
Erben, P; Faber, A; Hoedt, S; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, DJ; Sommer, U; Stern-Straeter, J1
Ammer, AG; Hayes, KE; Kelley, LC; Martin, KH; Walk, EL; Weed, SA1
Audring, H; Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Riess, H; Schwarz, M; Zuber, J1
Donato, NJ; Johnson, FM; Newman, RA; Yang, P1
Donato, NJ; Johnson, FM; Saigal, B1
Bruce, IA; Homer, JJ; McGown, AT; Slevin, NJ; Ward, TH1
Abdollahi, A; Bischof, M; Debus, J; Huber, PE; Krempien, R; Lindel, K; Lipson, KE; Milker-Zabel, S; Oertel, S; Peschke, P; Zabel, A1
Aguilera, J; An, Y; Chu, TS; Dang, CL; Ongkeko, WM; Wang-Rodriguez, J1
Altuna, X; Chu, TS; Lopez, JP; Ongkeko, WM; Wang-Rodriguez, J; Weisman, RA1
Baer, MR; Bowman, MJ; Liu, W; Morgan, J; Oseroff, AR; Pandey, RA; Pera, P; Zheng, X1
Bartkowiak, D; Hipp, PR; Mendonca, MS; Röttinger, EM1
Kutner, A; Milczarek, M; Wietrzyk, J1
Kawakami, Y; Kimura, H; Nakamura, K; Nishibu, A; Yamamoto, T; Yanagihori, H1

Reviews

2 review(s) available for imatinib mesylate and Carcinoma, Epidermoid

ArticleYear
Molecularly targeted therapies for nonmelanoma skin cancers.
    International journal of dermatology, 2013, Volume: 52, Issue:6

    Topics: Anilides; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyridines; Pyrimidines; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms

2013
The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer.
    Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:1

    Topics: Anilides; Antineoplastic Agents; Benzamides; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatofibrosarcoma; ErbB Receptors; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms, Squamous Cell; Piperazines; Pyridines; Pyrimidines; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck

2011

Trials

2 trial(s) available for imatinib mesylate and Carcinoma, Epidermoid

ArticleYear
Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms

2009
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Female; Gene Dosage; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Taxoids

2011

Other Studies

33 other study(ies) available for imatinib mesylate and Carcinoma, Epidermoid

ArticleYear
Evaluation of anti-EGFR potential of quinazoline derivatives using molecular docking: An in silico approach.
    Biotechnology and applied biochemistry, 2022, Volume: 69, Issue:3

    Topics: Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Ligands; Molecular Docking Simulation; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines

2022
Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017, Volume: 124, Issue:3

    Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Combined Modality Therapy; DNA Breaks, Double-Stranded; Head and Neck Neoplasms; HeLa Cells; Humans; Imatinib Mesylate; Immunoglobulin G; Integrin beta1; MCF-7 Cells; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck

2017
Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:2

    Topics: Aged, 80 and over; Benzamides; Carcinoma, Squamous Cell; Female; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Thymus Neoplasms

2014
Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Oncology reports, 2014, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Fluorouracil; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinases; Papillomavirus Infections; Piperazines; Pyrimidines

2014
Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate.
    The Journal of dermatology, 2015, Volume: 42, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Skin Neoplasms

2015
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Oncogene, 2016, 07-07, Volume: 35, Issue:27

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Gene Amplification; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Fibroblast Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays

2016
Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report.
    Tumori, 2016, Nov-11, Volume: 102, Issue:Suppl. 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Humans; Imatinib Mesylate; Laryngeal Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Neoplasm Staging; Neoplasms, Multiple Primary; Tomography, X-Ray Computed

2016
New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors.
    Anticancer research, 2016, Volume: 36, Issue:11

    Topics: Aged; Carcinoma, Squamous Cell; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Second Primary; Proto-Oncogene Mas; Skin Neoplasms

2016
Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
    Archives of otolaryngology--head & neck surgery, 2008, Volume: 134, Issue:9

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Immunoprecipitation; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines

2008
The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
    International journal of oncology, 2009, Volume: 34, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Enzyme-Linked Immunosorbent Assay; Female; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2009
Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas.
    The American journal of pathology, 2010, Volume: 176, Issue:2

    Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cell Proliferation; Cells, Cultured; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Transfection; Transplantation, Heterologous; Tumor Burden; Vascular Endothelial Growth Factor A

2010
C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.
    Chinese journal of cancer, 2010, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial Cells; Herpesvirus 4, Human; Heterozygote; Homozygote; Humans; Imatinib Mesylate; Introns; Mutation; Nasopharyngeal Neoplasms; Nasopharynx; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2010
Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Survival Rate; Taxoids; Treatment Outcome

2011
Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
    International journal of oncology, 2011, Volume: 38, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Vascular Endothelial Growth Factor A

2011
Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC.
    Oncology reports, 2011, Volume: 25, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Squamous Cell; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Matrix Metalloproteinase 2; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured

2011
Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Oncology reports, 2011, Volume: 26, Issue:5

    Topics: Adult; Angiogenic Proteins; Antineoplastic Agents; Benzamides; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Viral; Female; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Papillomavirus Infections; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Vascular Endothelial Growth Factor A

2011
Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Oncology reports, 2012, Volume: 27, Issue:1

    Topics: Antineoplastic Agents; Benzamides; beta Catenin; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Papillomavirus Infections; Piperazines; Pyrimidines; Signal Transduction; Stem Cell Factor; Viral Core Proteins

2012
HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers.
    Cancer research, 2011, Nov-01, Volume: 71, Issue:21

    Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Coculture Techniques; Culture Media, Conditioned; Disease Progression; Female; Fibroblasts; HeLa Cells; Heparin-binding EGF-like Growth Factor; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Mice, Nude; Neoplasm Proteins; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Stromal Cells; Tumor Cells, Cultured; Tyrphostins; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2011
Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia.
    The British journal of oral & maxillofacial surgery, 2012, Volume: 50, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Follow-Up Studies; Gingival Neoplasms; Humans; Hydroxyurea; Hypopharyngeal Neoplasms; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Neoplasms; Neoplasms, Second Primary; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Tongue Neoplasms

2012
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins

2012
Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma.
    Oncology reports, 2012, Volume: 28, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Carboplatin; Carcinoma, Squamous Cell; Cell Line, Tumor; Gene Expression; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Imatinib Mesylate; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Papillomavirus Infections; Piperazines; Pyrimidines

2012
Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.
    Oncogene, 2013, Volume: 32, Issue:40

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Extracellular Matrix; Head and Neck Neoplasms; Heparin-binding EGF-like Growth Factor; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Piperazines; Protein Kinases; Pyrimidines; src-Family Kinases

2013
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
    European journal of haematology, 2003, Volume: 70, Issue:4

    Topics: Age Factors; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cocarcinogenesis; Coronary Disease; Drug Eruptions; Dyspnea; Enzyme Inhibitors; Facial Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Sunlight; Ultraviolet Rays

2003
Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
    Journal of experimental therapeutics & oncology, 2004, Volume: 4, Issue:4

    Topics: Anti-Infective Agents, Local; Antineoplastic Agents; Arachidonic Acid; Benzamides; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Eicosanoids; Enzyme Activation; ErbB Receptors; Gentian Violet; Head and Neck Neoplasms; Humans; Imatinib Mesylate; MAP Kinase Kinase 1; Membrane Proteins; Piperazines; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Time Factors

2004
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Journal of cellular physiology, 2005, Volume: 205, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Head and Neck Neoplasms; Heparin-binding EGF-like Growth Factor; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Intercellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Stem Cell Factor

2005
Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer.
    Anti-cancer drugs, 2005, Volume: 16, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Cell Line, Tumor; Comet Assay; Drug Antagonism; Drug Synergism; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2005
Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2006, Volume: 182, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Endothelial Cells; Glioblastoma; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Transplantation, Heterologous; Tumor Stem Cell Assay

2006
Gleevec suppresses p63 expression in head and neck squamous cell carcinoma despite p63 activation by DNA-damaging agents.
    The Laryngoscope, 2006, Volume: 116, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Damage; Down-Regulation; Gene Expression; Genes, abl; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Membrane Proteins; Piperazines; Pyrimidines

2006
STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    The Laryngoscope, 2006, Volume: 116, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Mitosis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor

2006
The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Humans; Hypopharyngeal Neoplasms; Imatinib Mesylate; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2007
A radioprotective effect of imatinib (Gleevec) in human squamous carcinoma cells.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2007, Volume: 183, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Radiation Tolerance; Radiation-Protective Agents

2007
The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
    Oncology research, 2007, Volume: 16, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Calcitriol; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cisplatin; Dihydroxycholecalciferols; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Ergocalciferols; G1 Phase; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Resting Phase, Cell Cycle; Taxoids

2007
Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
    Acta dermato-venereologica, 2008, Volume: 88, Issue:2

    Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Multiple Primary; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Neoplasms

2008